

Curriculum Vitae

Robin Lester Carhart-Harris

December 2022

D.O.B: 31 August 1980 (42)

NATIONALITY: British

STATUS: Married. Two children.

PRESENT POSITION:

Ralph Metzner Distinguished Professor of Neurology and Psychiatry

Director of Psychedelics Division, Neuroscape

University of California, San Francisco (UCSF)

PAST POSITIONS:

Founder & Head of Centre for Psychedelic Research, Division of Psychiatry, Department of Brain Sciences, Faculty of Medicine, Imperial College London. April 2019-August 2021.

<http://www.imperial.ac.uk/psychedelic-research-centre/>

Associative Professor, Dept. of Psychiatry, University of Oxford. July 2018- Dec 2019

Research Fellow & Group Lead, Psychedelic Research Group, Imperial College London. 2015-2019

Research Associate, Neuropsychopharmacology, Imperial College London. 2009-2015

H-INDEX & CITATIONS:

As of December 2022:

H-index = 64

Citations = >18.7K

BRIEF BIOGRAPHY:

Robin is the Ralph Metzner Distinguished Professor in Neurology and Psychiatry and Director of Neuroscape's Psychedelics Division at the University of California, San Francisco. He moved to Imperial College London in 2008 after obtaining a PhD in

Psychopharmacology from the University of Bristol. Robin has designed human brain imaging studies with LSD, psilocybin, MDMA and DMT, and several clinical trials of psilocybin therapy for severe mental illnesses. Robin founded the Centre for Psychedelic Research at Imperial College London in April 2019, was ranked among the top 31 medical scientists in 2020, and in 2021, was named in TIME magazine's '100 Next' – a list of 100 rising stars shaping the future. His research is creating system-level change in mental health care.

ACADEMIC QUALIFICATIONS:

2005-09 **PhD** Psychopharmacology, Dept. Psychiatry, University of Bristol
2004-05 **MA** Psychoanalysis and Contemporary Society, Brunel University.
2001-04 **BSc** (Honours) Applied Psychology and Computing, Bournemouth University: 2.1.
1998-99 **A-levels:** Sociology, Psychology, Chemistry: A, B, C

FUNDING (**Bold** = PI on all donations unless otherwise stated):

Total: **>£4M**

2022 BBSRC, UK Research and Innovation, \$200K (Co-I)
2022 **Antonio Garcia \$236K**
2021 **Steve & Genevieve Jurveston \$250K**
2021 **Arctos Foundation \$50K**
2021 **Thomas Martin \$1.5K**
2021 **Albert Hobohm \$33K**
2021 **TRYP Therapeutics \$160K**
2021 **Beckley Psytech £150K**
2021 **Thomas Martin £50K**
2020 **Charlene Engelhard \$400K**
2020 **Ryan Zurrer \$60K**
2019 **Eric Grotefeld £20K**
2019 **Brian Rose/London Real £10K**
2019 **Christian Angermayer £150K**
2019 **Amanda Eilian \$10K**
2019 **Alex Mosley Trust £200K**
2019 **Tim Ferriss \$1M**

- 2019 **Anton Bilton £0.5M**
- 2019 **Singhal Foundation \$1.25M**
- 2018 **Tamas family \$1M**
- 2018 **Ad Astra Chandaria Foundation £0.25M**
- 2012 *MRC DCS grant £0.5M*

AWARDS & HONORS:

- 2022 *Nominated for academic/researcher of the year, 2022, Microdose.*
- 2021 *Publicly voted – (psychedelic medicine) academic/researcher of the year, 2021, Microdose*
(<https://microdose.buzz/news/the-1st-annual-microdose-awards/>)
- 2021 *TIME 100 Next, 2021:*
<https://time.com/collection/time100-next-2021/5937720/robin-carhart-harris/>
- 2020 *World's Top 31 medical scientists, The Times:*
<https://www.thetimes.co.uk/article/from-pandemics-to-cancer-the-science-power-list-d23bb9b2k>
- 2018 *ABAI, BF Skinner Award 2018*
- 2015 *Junior Clinical Award, British Association of Psychopharmacology*
- 2011 *Heffter Research Institute Award*
- 2010 *Multidisciplinary Association for Psychedelic Studies (MAPS) Award*
- 2009 *Neuropsychanalysis Foundation Award*
- 2008 *Bristol-Cardiff Young Neuroscientist Award*

TEACHING & SUPERVISION OVERVIEW:

NIDA, T32 Supervisor, UCSF, 2022

Lectures for Psychiatry Residents, UCSF, 2022

Lectures for UC Berkeley Masters Students, 2022

Supervised 4 PhDs to completion & 15+ Masters students

Imperial College London teaching 2011-2021:

BSc Medical Biosciences

MSc Experimental Neuroscience

MRes Experimental Neuroscience

Invited teaching for: Kings (Maudsley), UCL, Barts (BSc & Masters)

Clinical Psychology lecture, University of Oxford.

Current Supervision: Four PhD students, 5 MSc (Imperial), 5 interns.

PhD EXAMINER:

2020 Malin Uthaug, Maastricht University. 1st supervisor = Prof Jan Ramaekers.

Current Rayyan Zafar, Imperial College London, Internal Examiner.

ADVISORY & EDITORIAL BOARDS & COMMITTEES:

2022 Editorial Board, Neuropsychoanalysis

2022 Editorial Board, Frontiers in Human Neuroscience

2022 Fellow of the Atria Academy of Science and Medicine

2022 Advisory Editor, Neuropsychopharmacology

2022 Editorial Board, Biomedicines

2022 Supervisor & contributor to NIDA T32 Committee, UCSF

2020-21 Advice to UK government Special Advisors on psychedelic medicine

2020-21 Advice to FDA on psychedelic medicine

2020 Advisor to Drug Science Psychedelic working group

2020 Oregon Psilocybin Services Training Advisory Board

2020 Requested scientific advisor to Smallpharma©

2022 Scientific Advisor to Freedom Bio©

2022 Scientific advisor to MindState©

2020 Scientific advisor to TRYP Therapeutics©

2020-2022 Scientific advisor to EntheonBiomedical©

2020 Scientific advisor to Mydecine©

2019 Scientific advisor to Compass Pathways©

2019 Requested scientific advisor for Usona©

2019 Scientific advice for Otsuka©

- 2019 *Scientific advisor for Synthesis Institute* ©
- 2018 *European Medicine Agency. Scientific advisor to Compass Pathways* ©
- 2017 *Medicines & Healthcare Regulatory Authority (MHRA). Scientific advice for Eleusis* ©
- 2016-18 *MRes Translational Neuroscience. Organising Committee. Imperial College London*

MEMBERSHIPS & OTHER EDITORIAL BOARDS:

- 2022-2023 *Guest Editor, Scientific Reports*
- 2022-present *Journal of Psychedelic Medicine – Editorial Board*
- 2020-present *Member of Association for Psychological Science*
- 2020-present *Massachusetts General Hospital, Psychedelic Research Centre, Advisory Council member*
- 2015-present *Member of the Neuropsychoanalysis Association*
- 2016-present *Member of International Society for Research on Psychedelics*
- 2009-present *British Association for Psychopharmacology*
- 2012-present *Editorial Board: Journal of Psychopharmacology*
- 2011-present *Editorial Board: Journal of Neuropsychoanalysis*

CURRENT POSTDOCS:

- 2022-current *Dr Stal Shrestha (UCSF, T32 Fellow)*
- 2021-2022 *Dr Selen Atasoy (Imperial/Oxford)*
- 2020-2022 *Dr Taylor Lyons (UCSF)*
- 2020-current *Dr Balazs Szigeti (Imperial)*
- 2020-current *Dr Christopher Timmermann (Imperial)*
- 2019-current *Dr Leor Roseman (Imperial)*
- 2019-current *Dr Fernando Rosas (Imperial)*
- 2019-current *Dr Meg Spriggs (Imperial)*
- 2019-2022 *Dr Malin Uthaug (Imperial)*

VISITING POSTDOCS:

- 2019-2020 *Dr Charlotte Marshall, Coma Science Group, Liege University*

2014-2015 Dr Eduardo Schenberg, University of Sao Paulo

RESEARCH ASSOCIATES:

2020-21 Laura Kartner

2020-21 Keri Mans

2019-21 Hannes Kettner

2017-21 Bruna Giribaldi

SUPERVISED PhD STUDENTS (1st supervisor and Imperial - unless otherwise stated):

Graduated Leor Roseman, PhD

Graduated Mendel Kaelen, PhD

Graduated Christopher Timmermann, PhD

Graduated Taylor Lyons, PhD

2019-current Lisa Luan, PhD student

2019-current Julia Bornmann, PhD student

2020-current Hannah Douglas, PhD student (second supervisor)

2020-current Hannes Kettner, PhD student (Imperial/UCSF)

SUPERVISED IMPERIAL MASTERS STUDENTS

2020 Hannah Douglas, MSc Experimental Neuroscience

2020 Nadrah Mohamed-Izmi, MSc Experimental Neuroscience

2020 Will Roseby, MSc Experimental Neuroscience

2020 Faissal Sharif, MSc Experimental Neuroscience

2020 James Sexton, MSc Experimental Neuroscience

2019 Kevin Stevralia, MRes Translational Neuroscience

2019 Gregory Cooper, MSc Experimental Neuroscience

2019 Katie Trinci, MSc Experimental Neuroscience

2019 Pablo Mallaroni, MSc Experimental Neuroscience

2019 Joanna Kuc, MSc Experimental Neuroscience

2019 *Joe Peill, MSc Experimental Neuroscience*

2017 *Melissa Shukuroglou, MRes, Neuroscience*

2017 *Meghan Good, MRes, Experimental Neuroscience*

2017 *Jo Wagland, BSc Medicine, Imperial College London*

2016 *Lisa Evans, MRes Experimental Neuroscience*

2015 *Kabir Nigam, MRes Experimental Neuroscience*

2013 *Dr Stefan Brugger, Imperial graduate in Medicine*

2013 *Leor Roseman, MRes Experimental Neuroscience*

2012 *Tytus Murphy, MRes Neuroscience*

SUPERVISED EXTERNAL STUDENTS/INTERNS

2020 *Sebastian Hubner, MSc, Cognitive Science, University of Trento*

2019 *Keri Mans, MSc Clinical Neuropsychology, Maastricht University*

2019 *Richard Zeifman, Clinical. Psych trainee. Ryerson University, Canada*

2018 *Dana Geerts, MSc Neuropsychology, Maastricht University*

2018 *Manca Peskar, MSc Neuropsychology, Maastricht University*

2017 *Hannes Kettner, MSc Neuropsychology, Maastricht University*

2017 *Hannah Douglas, BSc Neuroscience, Leeds University*

2017 *Lea Mertens, MSc Neuropsychology, Maastricht University*

2017 *Laura Kartner, MSc Psychology, Julius-Maximilians-Universität Würzburg*

2016 *Cammy Mitchell, BSc Medicine, University of Cambridge*

2016 *Eline Haijin, MSc Neuropsychology, Maastricht University*

2016 *Anhjili Zhuparris, MSc Neuroscience, University of Amsterdam*

2016 *Philip Ashton, BSc Neuroscience, University of Aberdeen*

2016 *Sophie-Anne Fluri, MRes Experimental Neuroscience*

2016 *Bruna Cunha, BSc Pharmacology, UCL*

2015 *Lily Fitzgerald, Cambridge University, Biomedical student*

2015 *Jack Stroud, Oxford University, Biomedical student*

2015 *Catherine Scrace, BSc Neuroscience, Leeds University*

2014 *Dr Eduardo Schenberg. Visiting postdoc from Sao Paulo*

2013 *Rosa Sun, Cambridge University Medical Student*

2012 *Mendel Kaelen, MSc Neuroscience, University of Groningen*

2012 *Luke Williams, MSc Neuroscience, Birkbeck, University of London*

2011 *Ann-Mari Lilleløyken, MSc Mental Health Studies, Institute of Psychiatry, KCL*

2011 *Samuel Turton, Final year medical student, Sheffield University*

SELECTION OF INVITED PRESENTATIONS IN USA

2022 *University of Kansas, Grand Rounds, USA*

2022 *Moderated Fireside with Jerry Rosenbaum, Amherst College Reunion, USA*

2022 *NIH, Grand Rounds, Bethesda, USA*

2022 *Plenary - American Psychiatric Association, New Orleans, USA*

2022 *Keynote - Science of Consciousness conference, Tucson, Arizona, USA*

2022 *Plenary - Society for Biological Psychiatry, New Orleans, USA*

2022 *Atria, USA*

2022 *SXSW, Austin, Texas, USA*

2022 *AAAS, Philadelphia, USA*

2022 *UCSF Neurology, Grand Rounds, San Francisco, USA*

2021 *Tufts Medical School, Grand Rounds, Boston, USA*

2021 *Brain Institute, Chapman University, Irvine, California, USA*

2021 *UC Berkeley, Berkeley Neuroscience Conference, Berkeley, USA*

2021 *MacLean Hospital, Grand Rounds, Harvard Medical School, Boston, USA*

2021 *Columbia University, College of Physicians and Surgeons, Grand Rounds, NYC, USA*

2021 *University of Texas at Houston, Student Seminar, USA*

2020 *University of Arkansas for Medical Sciences, Grand Rounds, USA*

2020 *10th Annual Peter Miller Musser Lecture in Depression. MGH Grand Rounds, Boston, USA*

2020 *Psych Congress, Nashville, USA*

2020 *NACCME, Las Vegas, USA*

2020 *Horizon, NYC, USA*

2020 *City Arts & Literature, San Francisco, USA*

2020 *Radcliffe Institute, Harvard University, Cambridge, USA*

2020 *Harvard University, Boston, USA*

2020 *Dartmouth, Hanover, USA*

2019 *Milken Institute Global Conference, keynote speaker LA, USA*

2018 *Keynote, Psych Congress, Orlando, USA*

2018 *Keynote, Harvard Medical School, USA*

2018 *International Society for Affective Disorders, Houston, Texas, USA*

2018 *American Society for Clinical Psychopharmacology (ASCP), Miami, USA*

2018 *Los Angeles Psychedelic Symposium, LA, USA*

2018 *Science of Consciousness conference, Tucson, Arizona, USA*

2018 *BF Skinner Lecturer: Association for Behavior Analysis International (ABAI), San Diego, USA*

2017 *MAPS International conference: Oakland, California, USA*

2016 *Keynote, University of Michigan, USA*

2016 *University of Wisconsin-Madison, USA*

2016 *Centre for consciousness research, Arizona, USA*

2015 *American College of Neuropsychopharmacology, ACNP, Florida, USA*

2015 *Horizons: New perspectives on psychedelics in medicine, New York, USA*

2013 *MAPS: 'Psychedelic Science', Oakland California, USA*

2012 *Keynote, NIH, Bethesda, Maryland, USA*

2012 *Towards a Science of Consciousness, Plenary, Tuscon, Arizona, USA*

2011 *MAPS International Conference: San Jose, California, USA*

SELECTION OF INVITED PRESENTATIONS IN UK

2021 *Dept. Psychiatry, University of Cambridge*

2020 *Royal College of Psychiatrists, London*

2020 *British Neuropsychiatry Association (BNPA), London*

2019 *CUBRIC 2, Cardiff University*

2019 *Conduit Club, London*

2019 *Founders Forum, HeathTech, Havas, London*

2019 *Royal College Psychiatrists International Conference, Excel, London*

2019 *International Psychoanalysis Association Conference, London*

2018 *University of Cambridge, Behavioural and Clinical Neuroscience Institute*

2018- *Royal Institution, London. Charing 'How to Change your Mind' – Michael Pollan*

2018 *Wired Health, Crick Institute, London*

2017 *Royal College of Psychiatrists annual adult psychiatry meeting, Gateshead*

2017 *Cheltenham Science Festival*

2017 *International Society on Affective Disorders, KCL*

2017 *New Scientist Live – The Excel*

2017 *Royal College of Psychiatrists, Philosophy Special Interest meeting, London*

2017 *Royal College of Psychiatrists, - International Congress, Edinburgh*

2016 *Royal College of Psychiatrists, neuroscience interest group*

2016 *"Twilight Science" – The Royal Society, London*

2016 *"LSD Revealed" - The Royal Society, London*

2016 *TEDx - University of Warwick*

2016 *BAP, Annual meeting, Brighton*

2015 *"How to change the world", The Royal Institute, London*

2015 *British Neuroscience Association, Annual meeting, Edinburgh*

2015 *British Association for Psychopharmacology, Annual meeting, Bristol*

2014 *Centre for Cognitive Science, University of Sussex*

2014 *Society for General Microbiology (SGM) Annual Conference, Liverpool*

2013 *Institute of Psychiatry, KCL*

2013 *University of Liverpool, John Moores*

2013 *University Dept. of Pharmacology, Oxford University*

2013 *British Neuropsychiatry Association annual meeting, London*

2012 *Association for the Scientific Study of Consciousness meeting in Brighton*

2012 *Brain meeting: Functional Imaging Laboratory, UCL*

SELECTION OF INVITED PRESENTATIONS IN REST OF WORLD:

- 2020 *Collision, Toronto, Canada*
- 2020 *Web Summit, Lisbon, Portugal*
- 2020 *Mind Medicine, Melbourne, Australia*
- 2019 *Web Summit, Lisbon, Portugal*
- 2019 *British Embassy, Lisbon, Portugal, Speaker for GREAT Briton's initiative*
- 2019 *Flor-Henry keynote Speaker, Edmonton, Canada*
- 2019 *ECNP invited presentation, Copenhagen, Denmark*
- 2019 *Keynote, World Economic Forum, Davos, Switzerland*
- 2018 *Keynote, Psychedelic Psychotherapy Forum Victoria British Columbia, Canada*
- 2018 *Keynote, Special Lecture, University of British Columbia, Vancouver, Canada*
- 2018 *CINP, Vienna, Austria*
- 2017 *Guest Lecture at University of Toronto Dept Psychiatry, Canada*
- 2017 *Max Planck Society Visions in Science conference, Max Planck Institute, Berlin, Germany*
- 2017 *Brain and Mind meeting, University of Helsinki, Finland*
- 2017 *International Convention of Psychological Science, Vienna, Austria*
- 2016 *Sjobring Lecture, Lund University, Sweden*
- 2016 *Nights conference, Berlin, Germany*
- 2016 *Keynote, Karolinska Institute, Stockholm, Sweden*
- 2016 *ECNP annual congress, Vienna, Austria*
- 2016 *Interdisciplinary conference for psychedelic research, Amsterdam, Netherlands*
- 2015 *Association for the scientific study of consciousness, Paris, France*
- 2015 *Society of Neuroscience, Buenos Aires, Argentina*
- 2015 *Cimbi Symposium, Copenhagen, Denmark*
- 2015 *Keynote, Champalimaud hospital, Lisbon, Portugal*
- 2015 *Keynote, Czech psychedelic society. Brno/Prague, Czech Republic*
- 2015 *Keynote, Irish psychedelic society, Dublin, Ireland*
- 2015 *Keynote, SINAPSA, Ljubljana, Slovenia*
- 2014 *Studying Consciousness in Developmental age, Rome, Italy*

- 2014 *European Congress of Psychiatry, Munich, Germany*
- 2014 *Bergen Student Society in Bergen, Norway*
- 2013 *Neuroday, Copenhagen, Denmark*
- 2013 *International Symposium on Medicinal Plants in Psychiatry, University of São Paulo, Brazil*
- 2013 *The Brain: criticality, dynamics, networks and function, University of Naples, Italy*
- 2011 *Neuropsychanalysis annual international symposium, Berlin, Germany*
- 2011 *Dept. of Epileptology, University of Bonn, Germany*

SELECTION OF PUBLIC ENGAGEMENT INITIATIVES:

- 2022 *Interviewed by Deepak Chopra: <https://www.youtube.com/watch?v=wx4a9YZ9ajc>*
- 2022 *Featured in Nature articles: <https://www.nature.com/articles/d41586-022-02874-7>*
- 2022 *Featured in Wired article: <https://www.wired.co.uk/article/psychedelic-hype-bubble>*
- 2022 *Featured in PBS documentary: <https://www.pbs.org/wgbh/nova/video/can-psychedelics-cure/>*
- 2022 *Featured in Netflix series: <https://www.youtube.com/watch?v=X8LRb4jfZ9g>*
- 2022 *BBC coverage of Nature Medicine paper: <https://www.bbc.com/news/health-61070591>*
- 2022 *New York Times coverage of Nature Medicine paper:
<https://www.nytimes.com/2022/04/11/health/psilocybin-depression.html>*
- 2022 *Press release with UCSF for new Nature Medicine paper:
<https://www.ucsf.edu/news/2022/04/422606/psilocybin-rewires-brain-people-depression>*
- 2021 *Personally commissioned piece for Freuds Journal: <https://www.freudsjournals.com/howlovewins-self-understanding-through-revelation>*
- 2021 *Personally commissioned piece for The i Newspaper: https://inews.co.uk/opinion/psychedelic-drug-trials-magic-mushrooms-treat-depression-challenge-will-be-undoing-stigma-1023804?ito=twitter_share_article-top*
- 2021 *Personally commissioned piece for The Guardian:
<https://www.theguardian.com/commentisfree/2021/apr/20/psychedelics-depression-treatment-psychiatry-psilocybin>*
- 2021 *Personally commissioned piece for San Francisco Business Times:
<https://www.bizjournals.com/sanfrancisco/news/2021/05/28/psychedelics-ucsf-mdma-psilocybin-neuroscape.html>*
- 2021 *TIME NEXT 100: <https://time.com/collection/time100-next-2021/5937720/robin-carhart-harris/>*
- 2020 *Science power list (top 31 medical scientists): <https://www.thetimes.co.uk/article/from-pandemics-to-cancer-the-science-power-list-d23bb9b2k>*

- 2020 *Wired World 2021 – commissioned piece:* <https://www.wired.co.uk/article/psychedelics-big-pharma>
- 2020 *Personally commissioned piece for The Guardian:*
<https://www.theguardian.com/commentisfree/2020/jun/08/psychedelic-drugs-treat-depression>
- 2020 *Sean Carroll podcast:* <https://www.preposterousuniverse.com/podcast/2020/02/03/82-robin-carhart-harris-on-psychedelics-and-the-brain/>
- 2020 *Daniel Carcillo podcast:* <https://www.youtube.com/watch?v=VMIHIM8vB74>
- 2019 *The Telegraph:* <https://www.telegraph.co.uk/health-fitness/mind/can-magic-mushrooms-really-cure-depression/>
- 2019 *The Independent:* <https://www.independent.co.uk/news/health/magic-mushroom-depression-psychedelic-drug-mental-health-antidepressant-big-pharma-imperial-ld-dmt-a8929796.html>
- 2019 *Guardian:* <https://www.theguardian.com/science/2019/jun/10/magic-mushrooms-treatment-depression-aztecs-psilocybin-mental-health-medicine>
- 2018 *The Times:* <https://www.thetimes.co.uk/article/could-you-treat-your-depression-by-tripping-on-magic-mushrooms-fgh672l5k>
- 2018 *Wired:* <http://www.wired.co.uk/article/psychedelics-ld-depression-anxiety-addiction>
- 2018 *Magic Medicine documentary:* <https://vimeo.com/ondemand/magicmedicine>
- 2017 *Russell Brand Podcast interview:* <https://www.youtube.com/watch?v=O9vNDRGveYs>
- 2017 *Guardian:* <https://www.theguardian.com/us-news/2017/nov/25/magic-mushrooms-decriminalization-california>
- 2017 *New Scientist:* https://www.newscientist.com/round-up/psychedelic-medicine/?intcmp=PAC%7CNSNS%7C2017-inlinelink_main-feat&utm_medium=PAC&utm_source=Twitter&utm_campaign=Echobox&cmpid=SOC%7CNSNS%7C2017-Echobox
- 2017 *National Geographic: Breakthrough – episode 1: Addiction: Psychedelic cure?*
<http://channel.nationalgeographic.com/breakthrough-series/episodes/addiction-a-psychedelic-cure/>
- 2017 *The Independent:* <http://www.independent.co.uk/news/science/ld-first-evidence-higher-level-consciousness-hallucinogenic-drug-scientists-a7690366.html>
- 2016 *TIME:* <http://time.com/4338947/magic-mushrooms-for-depression/>
- 2016 *BBC Newsnight:* <https://www.youtube.com/watch?v=JHbVSclR5qk>
- 2016 *TEDx Warwick:* <https://www.youtube.com/watch?v=MZlaTaNR3gk>
- 2016 *CNN:* <http://edition.cnn.com/videos/tv/2016/04/13/exp-ld-researcher.cnn>
- 2016 *Today Programme, BBC Radio 4:* <http://www.bbc.co.uk/programmes/p03qsx61>
- 2016 *Telegraph:* <http://www.telegraph.co.uk/news/science/12146975/Taking-LSD-leads-to-improved-psychological-wellbeing-study.html>

- 2015 *How to Change the World - Michael Pollan (itution):* <https://vimeo.com/154290924>
- 2015 *The Guardian:* <http://www.theguardian.com/society/2015/apr/26/lsd-amanda-feilding-depression-anxiety-science>
- 2015 *"How to change the world", The Royal Institute, London:* <https://vimeo.com/154290924>
- 2015 *The New Yorker:* <http://www.newyorker.com/magazine/2015/02/09/trip-treatment>
- 2014 *Independent on Sunday, Cover Story in New Review magazine:*
<http://www.independent.co.uk/news/people/dr-robin-carhartharris-is-the-first-scientist-in-over-40-years-to-test-lsd-on-humans--and-youre-next-9667532.html>
- 2014 *The Observer:* <http://www.theguardian.com/society/2014/oct/05/healing-trip-psychedelic-drugs-treat-depression>
- 2014 *Sciencemag.org:* <https://www.sciencemag.org/content/345/6192/18.full.pdf>
- 2014 *CNN:* <http://edition.cnn.com/2014/09/17/health/magic-mushroom-chemical-depression/>
- 2014 *The Conversation:*
<https://theconversation.com/magic-mushrooms-expand-your-mind-and-amplify-your-brains-dreaming-areas-heres-how-28754>
- 2014 *Washington Post:* <http://www.washingtonpost.com/news/to-your-health/wp/2014/07/03/psychedelic-drugs-put-your-brain-in-a-waking-dream-study-finds/>
- 2014 *Daily Mail:* <http://www.dailymail.co.uk/health/article-2679030/Are-magic-mushrooms-key-treating-depression-Brain-scans-reveal-psychedelic-drug-trips-induce-optimistic-dream-like-thinking.html>
- 2014 *Wall Street Journal article, "Psychedelics lead to a new vision of consciousness":*
<http://online.wsj.com/news/articles/SB10001424052702304626804579362953234754182>
- 2014 *Wellcome Trust: "Edges of consciousness" drama & science initiative. Radio drama commissioned & broadcast:* <https://www.bbc.co.uk/programmes/b06j67y0>
- 2013 *Daily Telegraph:* <http://www.telegraph.co.uk/science/9565026/Can-LSD-cure-depression.html>
- 2013 *Scientific American Mind:* <http://www.scientificamerican.com/article.cfm?id=hallucinogens-could-ease-existential-terror>
- 2013 *Wired:* <http://www.wired.com/wiredscience/2013/04/psychedlic/all/>
- 2013 *Imperial Festival:* <http://www.youtube.com/watch?v=jT5dZDnJ6J4>
- 2013 *London Real interview:* <http://www.youtube.com/watch?v=GMjtAu1IqOg>
- 2013 *IAm Q&A on Reddit.com.*
http://www.reddit.com/r/IAMa/comments/19j3fp/iam_dr_robin_carhartharris_from_imperial_college/
- 2012 *Open Foundation:* <https://www.youtube.com/watch?v=uMRG5KFZkKw>
- 2012 *Imperial College London re MDMA research:* <https://www.youtube.com/watch?v=CX5Uw4-bW-o>

- 2012 Science of Consciousness. Tuscon, Arizona. <https://www.youtube.com/watch?v=s7aieKPyP8c>
- 2012 BBC news, live interview: <http://www.bbc.co.uk/news/health-16694061>
- 2012 Channel 4: Drugs Live: the MDMA trial: <http://www.youtube.com/watch?v=4coPYeGs2y4>
- 2011 BBC 2, The Brain – a secret history: http://www.youtube.com/watch?v=gWM09s5_Z-A
- 2012-18 Regular Speaker for Pint of Science & Imperial Festival

PUBLICATION LIST (not including papers in prep or under review):

https://scholar.google.com/citations?user=7_MD_w0AAAAJ&hl=en

As of November 2022:

H-index = 64

Citations = >18.7K

Red font = papers in journals with Impact Factors > 79

146. Luppi AI, Rosas FE, Noonan MP, Mediano PAM, Kringelbach ML, **Carhart-Harris RL**, Stamatakis EA, Vernon AC, Turkheimer FE (2022) Oxygen and the Spark of Human Brain Evolution: Complex Interactions of Metabolism and Cortical Expansion across Development and Evolution. *Neuroscientist*. doi: 10.1177/10738584221138032.

145. Shukuroglou M, Roseman L, Wall M, Nutt D, Kaelen M, **Carhart-Harris R** (2022). Changes in music-evoked emotion and ventral striatal functional connectivity after psilocybin therapy for depression. *J Psychopharmacol.* doi: 10.1177/02698811221125354.

144. Kanen JW, Luo Q, Rostami Kandroodi M, Cardinal RN, Robbins TW, Nutt DJ, **Carhart-Harris RL**, den Ouden HEM (2022) Effect of lysergic acid diethylamide (LSD) on reinforcement learning in humans. *Psychol Med.* 1-12. doi: 10.1017/S0033291722002963.

143. Spriggs MJ, Giribaldi B, Lyons T, Rosas FE, Kärtner LS, Buchborn T, Douglass HM, Roseman L, Timmermann C, Erritzoe D, Nutt DJ, **Carhart-Harris RL** (2022) Body mass index (BMI) does not predict responses to psilocybin. *J Psychopharmacol.* doi: 10.1177/02698811221131994.

142. Goodwin GM... Carhart-Harris R ... Malievskaia E (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. *N Engl J Med.* 387(18):1637-1648. doi: 10.1056/NEJMoa2206443.

141. SP Singleton, AI Luppi, **RL Carhart-Harris**, J Cruzat, L Roseman, DJ Nutt, G Deco, ML Kringelbach, EA Stamatakis & A Kuceyeski (2022) Receptor-informed network control theory links LSD and psilocybin to a flattening of the brain's control energy landscape. *Nature Communications* 13. 5812.

140. Rajpal H, Mediano PAM, Rosas FE, Timmermann CB, Brugger S, Muthukumaraswamy S, Seth AK, Bor D, **Carhart-Harris RL**, Jensen HJ (2022) Psychedelics and schizophrenia: Distinct alterations to Bayesian inference. *Neuroimage*. doi: 10.1016/j.neuroimage.2022.119624.

139. Eckernäs E, Timmermann C, **Carhart-Harris R**, Röshammar D, Ashton M (2022) Population pharmacokinetic/pharmacodynamic modelling of the psychedelic experience induced by N,N-dimethyltryptamine - implications for dose considerations. *Clin Transl Sci*. doi: 10.1111/cts.13410.

138. Barba T, Buehler S, Kettner H, Radu C, Cunha BG, Nutt DJ, Erritzoe D, Roseman L, **Carhart-Harris R** (2022) Effects of psilocybin versus escitalopram on rumination and thought suppression in depression. *BJPsych Open*. 8(5):e163. doi: 10.1192/bjo.2022.565.

137. Watts R, Kettner H, Geerts D, Gandy S, Kartner L, Mertens L, Timmermann C, Nour MM, Kaelen M, Nutt D, **Carhart-Harris R**, Roseman L (2022) The Watts Connectedness Scale: a new scale for measuring a sense of connectedness to self, others, and world. *Psychopharmacology (Berl)*. doi: 10.1007/s00213-022-06187-5.

136. Nygart VA, Pommerenke LM, Haijen E, Kettner H, Kaelen M, Mortensen EL, Nutt DJ, **Carhart-Harris RL**, Erritzoe D (2022) Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample. *J Psychopharmacol*. 36(8):932-942. doi: 10.1177/02698811221101061.

135. Lawrence DW, **Carhart-Harris R**, Griffiths R, Timmermann C (2022) Phenomenology and content of the inhaled N, N-dimethyltryptamine (N, N-DMT) experience. *Sci Rep*. 12(1):8562. doi: 10.1038/s41598-022-11999-8.

134. Mediano PAM, Rosas FE, Luppi AI, Jensen HJ, Seth AK, Barrett AB, **Carhart-Harris RL**, Bor D (2022) Greater than the parts: a review of the information decomposition approach to causal emergence. *Philos Trans A Math Phys Eng Sci*. 380(2227):20210246. doi: 10.1098/rsta.2021.0246.

133. McCulloch DE, Knudsen GM, Barrett FS, Doss MK, **Carhart-Harris RL**, Rosas FE, Deco G, Kringelbach ML, Preller KH, Ramaekers JG, Mason NL, Müller F, Fisher PM (2022) Psychedelic Resting-state Neuroimaging: A Review and Perspective on Balancing Replication and Novel Analyses. *Neurosci Biobehav Rev*. doi:10.1016/j.neubiorev.2022.104689.

132. Girn M, Roseman L, Bernhardt B, Smallwood J, **Carhart-Harris R**, Spreng RN (2022) Serotonergic psychedelic drugs LSD and psilocybin reduce the hierarchical differentiation of unimodal and transmodal cortex. *Neuroimage*. doi: 10.1016/j.neuroimage.2022.119220.

131. Murphy R, Kettner H, Zeifman R, Giribaldi B, Kartner L, Martell J, Read T, Murphy-Beiner A, Baker-Jones M, Nutt D, Erritzoe D, Watts R, **Carhart-Harris R** (2022) Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression. *Front Pharmacol*. doi: 10.3389/fphar.2021.788155.

130. Daws RE, Timmermann C, Giribaldi B, Sexton JD, Wall MB, Erritzoe D, Roseman L, Nutt D, Carhart-Harris R (2022) Increased global integration in the brain after psilocybin therapy for depression. Nature Medicine. doi: 10.1038/s41591-022-01744-z.

129. Eckernäs E, Bendrioua A, Cancellorini C, Timmermann C, **Carhart-Harris R**, Hoffmann KJ, Ashton M (2022) Development and application of a highly sensitive LC-MS/MS method for simultaneous quantification of N,N-dimethyltryptamine and two of its metabolites in human plasma. *J Pharm Biomed Anal*. 212:114642. doi: 10.1016/j.jpba.2022.114642.

128. Toker D, Pappas I, Lendner JD, Frohlich J, Mateos DM, Muthukumaraswamy S, **Carhart-Harris R**, Paff M, Vespa PM, Monti MM, Sommer FT, Knight RT, D'Esposito M (2022) Consciousness is supported by near-critical slow cortical electro-dynamics. *Proc Natl Acad Sci U S A*. 119(7):e2024455119. doi: 10.1073/pnas.2024455119.

127. Peill JM, Trinci KE, Kettner H, Mertens LJ, Roseman L, Timmermann C, Rosas FE, Lyons T, **Carhart-Harris RL** (2022) Validation of the Psychological Insight Scale: A new scale to assess psychological insight following a psychedelic experience. *J Psychopharmacol*. doi: 10.1177/026988112111066709.

126. Weiss B, Nygart V, Pommerencke LM, **Carhart-Harris RL**, Erritzoe D (2021) Examining Psychedelic-Induced Changes in Social Functioning and Connectedness in a Naturalistic Online Sample Using the Five-Factor Model of Personality. *Front Psychol*. 12:749788. doi: 10.3389/fpsyg.2021.749788.

125. Bornemann J, Close JB, Spriggs MJ, **Carhart-Harris R**, Roseman L (2021) Self-Medication for Chronic Pain Using Classic Psychedelics: A Qualitative Investigation to Inform Future Research. *Front Psychiatry*. 12:735427. doi: 10.3389/fpsyg.2021.735427.

124. Timmermann C, Kettner H, Letheby C, Roseman L, Rosas FE, **Carhart-Harris RL** (2021) Psychedelics alter metaphysical beliefs. *Sci Rep*. 11(1):22166. doi: 10.1038/s41598-021-01209-2.

123. Luppi AI, Mediano PAM, Rosas FE, Harrison DJ, **Carhart-Harris RL**, Bor D, Stamatakis EA (2021) What it is like to be a bit: an integrated information decomposition account of emergent mental phenomena. *Neurosci Conscious* (2):niab027. doi: 10.1093/nc/niab027.

122. Spriggs MJ, Douglass HM, Park RJ, Read T, Danby JL, de Magalhães FJC, Alderton KL, Williams TM, Blemings A, Lafrance A, Nicholls DE, Erritzoe D, Nutt DJ, **Carhart-Harris RL** (2021) Study Protocol for "Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study." *Front Psychiatry*. 12:735523. doi: 10.3389/fpsy.2021.735523.

121. Kuc J, Kettner H, Rosas F, Erritzoe D, Haijen E, Kaelen M, Nutt D, **Carhart-Harris RL** (2021) Psychedelic experience dose-dependently modulated by cannabis: results of a prospective online survey. *Psychopharmacology (Berl)*. doi: 10.1007/s00213-021-05999-1.

120. Close JB., Bornemann J, Piggitt M, Jayacodi S, Luan LX, **Carhart-Harris R**, Spriggs M (2021) Co-design of Guidance for Patient and Public Involvement in Psychedelic Research. *Frontiers in Psychiatry*. DOI=10.3389/fpsy.2021.727496

119. Zamani A, **Carhart-Harris R**, Christoff K (2021) Prefrontal contributions to the stability and variability of thought and conscious experience. *Neuropsychopharmacology*. doi: 10.1038/s41386-021-01147-7.

118. Carhart-Harris R, Blemings A, Nutt DJ (2021) Psilocybin for Depression. Reply. N Engl J Med. 385(9):863-864. doi: 10.1056/NEJMc2108082.

117. Martial C, Fontaine G, Gosseries O, **Carhart-Harris R**, Timmermann C, Laureys S, Cassol H (2021) Losing the Self in Near-Death Experiences: The Experience of Ego-Dissolution. *Brain Sci*. 11(7):929. doi: 10.3390/brainsci11070929.

116. Kočárová R, Horáček J, **Carhart-Harris R** (2021) Does Psychedelic Therapy Have a Transdiagnostic Action and Prophylactic Potential? *Front Psychiatry*. 12:661233. doi: 10.3389/fpsy.2021.661233.

115. Hübner S, Haijen E, Kaelen M, **Carhart-Harris RL**, Kettner H (2021) Turn on, Tune in, and Drop out: Predictors of Attrition in a Prospective Observational Cohort Study on Psychedelic Use. *J Med Internet Res*. 23(7):e25973. doi: 10.2196/25973.

114. Mans K, Kettner H, Erritzoe D, Haijen ECHM, Kaelen M, **Carhart-Harris RL** (2021) Sustained, Multifaceted Improvements in Mental Well-Being Following Psychedelic Experiences in a Prospective Opportunity Sample. *Front Psychiatry*. 12:647909. doi: 10.3389/fpsy.2021.647909. eCollection 2021.

113. Simonsson O, Osika W, **Carhart-Harris R**, Hendricks PS (2021) Associations between lifetime classic psychedelic use and cardiometabolic diseases. *Sci Rep.* 2021 Jul 13;11(1):14427. doi: 10.1038/s41598-021-93787-4.
112. Roseman L, Ron Y, Saca A, Ginsberg N, Luan L, Karkabi N, Doblin R, **Carhart-Harris R** (2021) Relational Processes in Ayahuasca Groups of Palestinians and Israelis. *Front Pharmacol* 12:607529. doi: 10.3389/fphar.2021.607529.
111. Teixeira PJ, Johnson MW, Timmermann C, Watts R, Erritzoe D, Douglass H, Ketner H, **Carhart-Harris R** (2021) Psychedelics and health behaviour change. *J Psychopharmacol* 2698811211008554. doi: 10.1177/02698811211008554.
110. Kettner H, Rosas FE, Timmermann C, Kärtner L, **Carhart-Harris RL**, Roseman L (2021) Psychedelic Communitas: Intersubjective Experience During Psychedelic Group Sessions Predicts Enduring Changes in Psychological Wellbeing and Social Connectedness. *Front Pharmacol* 12:623985. doi: 10.3389/fphar.2021.623985.
109. **Carhart-Harris RL**, Wagner AC, Agrawal M, Kettner H, Rosenbaum JF, Gazzaley A, Nutt DJ, Erritzoe D (2021) Can pragmatic research, real-world data and digital technologies aid the development of psychedelic medicine? *J Psychopharmacol.* doi: 10.1177/02698811211008567.
- 108. Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, Martell J, Blemings A, Erritzoe D, Nutt DJ (2021) Trial of Psilocybin versus Escitalopram for Depression. *N Engl J Med.* 384(15):1402-1411. doi: 10.1056/NEJMoa2032994.**
107. Beaussant Y, Tulskey J, Guérin B, Schwarz-Plaschg C, Sanders JJ; Radcliffe Institute for Advanced Study Working Group on Psychedelic Research in Serious Illness (2021) Mapping an Agenda for Psychedelic-Assisted Therapy Research in Patients with Serious Illness. *J Palliat Med.* doi: 10.1089/jpm.2020.0764.
106. Simonsson O, Hendricks PS, **Carhart-Harris R**, Kettner H, Osika W (2021) Association Between Lifetime Classic Psychedelic Use and Hypertension in the Past Year. *Hypertension* doi: 10.1161/HYPERTENSIONAHA.120.16715.
105. Szigeti B, Kärtner L, Blemings A, Rosas F, Feilding A, Nutt DJ, **Carhart-Harris RL**, Erritzoe D (2021) Self-blinding citizen science to explore psychedelic microdosing. *Elife* 10:e62878. doi: 10.7554/eLife.62878.
104. Jobst BM, Atasoy S, Ponce-Alvarez A, Sanjuán A, Roseman L, Kaelen M, **Carhart-Harris R**, Kringelbach ML, Deco G (2021) Increased sensitivity to strong perturbations in a whole-brain model of LSD. *Neuroimage.* doi: 10.1016/j.neuroimage.2021.117809.

103. Pallavicini C, Cavanna F, Zamberlan F, de la Fuente LA, Ilksoy Y, Perl YS, Arias M, Romero C, **Carhart-Harris R**, Timmermann C, Tagliazucchi E (2021) Neural and subjective effects of inhaled N,N-dimethyltryptamine in natural settings. *J Psychopharmacol*. doi: 10.1177/0269881120981384.
102. Lawrence DW, Sharma B, Griffiths RR, **Carhart-Harris R** (2021) Trends in the Top-Cited Articles on Classic Psychedelics. *J Psychoactive Drugs* 1-16. doi: 10.1080/02791072.2021.1874573.
101. Kaertner LS, Steinborn MB, Kettner H, Spriggs MJ, Roseman L, Buchborn T, Balaet M, Timmermann C, Erritzoe D, **Carhart-Harris RL** (2021) Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing. *Sci Rep*. doi: 10.1038/s41598-021-81446-7.
100. Rosas FE, Mediano PAM, Jensen HJ, Seth AK, Barrett AB, **Carhart-Harris RL**, Bor D (2020) Reconciling emergences: An information-theoretic approach to identify causal emergence in multivariate data. *PLoS Comput Biol*. 2020 doi: 10.1371/journal.pcbi.1008289.
99. Luppi AI, **Carhart-Harris RL**, Roseman L, Pappas I, Menon DK, Stamatakis EA (2020) LSD alters dynamic integration and segregation in the human brain. *Neuroimage*. doi: 10.1016/j.neuroimage.2020.117653.
98. Rosas FE, Mediano PAM, Jensen HJ, Seth AK, Barrett AB, **Carhart-Harris RL**, Bor D (2020) Reconciling emergences: An information-theoretic approach to identify causal emergence in multivariate data. *PLoS Comput Biol*. doi: 10.1371/journal.pcbi.1008289.
97. Gandy S, Forstmann M, **Carhart-Harris RL**, Timmermann C, Luke D, Watts R (2020) The potential synergistic effects between psychedelic administration and nature contact for the improvement of mental health. *Health Psychol Open*. doi: 10.1177/2055102920978123.
96. Sanz C, Pallavicini C, Carrillo F, Zamberlan F, Sigman M, Mota N, Copelli M, Ribeiro S, Nutt D, **Carhart-Harris R**, Tagliazucchi E (2020) The entropic tongue: Disorganization of natural language under LSD. *Conscious Cogn*. doi: 10.1016/j.concog.2020.103070.
95. Brouwer A, **Carhart-Harris RL** (2020) Pivotal mental states. *J Psychopharmacol* doi: 10.1177/0269881120959637.
94. Andersen KAA, **Carhart-Harris R**, Nutt DJ, Erritzoe D (2020) Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies. *Acta Psychiatr Scand*. doi: 10.1111/acps.13249.

93. Herzog R, Mediano PAM, Rosas FE, **Carhart-Harris R**, Perl YS, Tagliazucchi E, Cofre R (2020) A mechanistic model of the neural entropy increase elicited by psychedelic drugs. *Sci Rep* 10(1):17725. doi: 10.1038/s41598-020-74060-6.
92. Alamia A, Timmermann C, VanRullen R, **Carhart-Harris RL** (2020) DMT alters cortical travelling waves. *Elife*. doi: 10.7554/eLife.59784.
91. Leptourgos P, Fortier-Davy M, Carhart-Harris R, Corlett PR, Dupuis D, Halberstadt AL, Kometer M, Kozakova E, Larøi F, Noorani TN, Preller KH, Waters F, Zaytseva Y, Jardri R (2020) Hallucinations Under Psychedelics and in the Schizophrenia Spectrum: An Interdisciplinary and Multiscale Comparison. *Schizophr Bull* doi: 10.1093/schbul/sbaa117
90. Zeifman RJ, Wagner AC, Watts R, Kettner H, Mertens LJ, **Carhart-Harris RL** (2020) Post-Psychedelic Reductions in Experiential Avoidance Are Associated With Decreases in Depression Severity and Suicidal Ideation. *Front Psychiatry*. 782. doi: 10.3389/fpsyt.2020.00782
89. Spriggs MJ, Kettner H, **Carhart-Harris RL** (2020) Positive effects of psychedelics on depression and wellbeing scores in individuals reporting an eating disorder. *Eat Weight Disord*. doi: 10.1007/s40519-020-01000-8.
88. Nutt D, **Carhart-Harris R** (2020) The Current Status of Psychedelics in Psychiatry. *JAMA Psychiatry*. doi: 10.1001/jamapsychiatry.2020.2171.
87. Varley TF, **Carhart-Harris R**, Roseman L, Menon DK, Stamatakis EA (2020) Serotonergic psychedelics LSD & psilocybin increase the fractal dimension of cortical brain activity in spatial and temporal domains. *Neuroimage*.
86. Borissova A, Ferguson B, Wall MB, Morgan CJ, **Carhart-Harris RL**, Bolstridge M, Bloomfield MA, Williams TM, Feilding A, Murphy K, Tyacke RJ, Erritzoe D, Stewart L, Wolff K, Nutt D, Curran HV, Lawn W (2020) Acute effects of MDMA on trust, cooperative behaviour and empathy: A double-blind, placebo-controlled experiment. *J Psychopharmacol* 269881120926673.
85. Kringelbach ML, Cruzat J, Cabral J, Knudsen GM, **Carhart-Harris R**, Whybrow PC, Logothetis NK, Deco G (2020) Dynamic coupling of whole-brain neuronal and neurotransmitter systems. *Proc Natl Acad Sci U S A*. 117(17):9566-9576. doi: 10.1073/pnas.1921475117
84. Nutt D, Erritzoe D, **Carhart-Harris R** (2020) Psychedelic Psychiatry's Brave New World. *Cell*. 181(1):24-28. doi: 10.1016/j.cell.2020.03.020.

83. Girn M, Mills C, Roseman L, **Carhart-Harris RL**, Christoff K (2020) Updating the dynamic framework of thought: Creativity and psychedelics. *Neuroimage* 116726.
82. Mertens LJ, Wall MB, Roseman L, Demetriou L, Nutt DJ, **Carhart-Harris RL** (2020) Therapeutic mechanisms of psilocybin: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression. *J Psychopharmacol* 34(2):167-180.
81. Kettner H, Gandy S, Haijen ECHM, **Carhart-Harris RL** (2019) From Egoism to Ecoism: Psychedelics Increase Nature Relatedness in a State-Mediated and Context-Dependent Manner. *Int J Environ Res Public Health* 16(24). pii: E5147
80. Barnett L, Muthukumaraswamy SD, **Carhart-Harris RL**, Seth AK (2019) Decreased directed functional connectivity in the psychedelic state. *Neuroimage* 116462.
79. Family N, Maillet EL, Williams LTJ, Krediet E, **Carhart-Harris RL**, Williams TM, Nichols CD, Goble DJ, Raz S (2019) Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers. *Psychopharmacology (Berl)*.
78. Timmermann C, Roseman L, Schartner M, Milliere R, Williams L, Erritzoe D, Muthukumaraswamy S, Ashton M, Bendrioua A, Kaur O, Turton S, Nour M, Day C, Leech R, Nutt D and **Carhart-Harris R** (2019) Neural correlates of the DMT experience assessed with multivariate EEG. *Scientific Reports*.
77. Roseman L, Haijen E, Idialu-Ikato K, Kaelen M, Watts R, **Carhart-Harris R** (2019) Emotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory. *J Psychopharmacol*.
76. Pallavicini C, Vilas MG, Villarreal M, Zamberlan F, Muthukumaraswamy S, Nutt D, **Carhart-Harris R**, Tagliazucchi E (2019) Spectral signatures of serotonergic psychedelics and glutamatergic dissociatives. *Neuroimage*. 200:281-291.
75. Russ SL, **Carhart-Harris RL**, Maruyama G, Elliott MS (2019) Replication and extension of a model predicting response to psilocybin. *Psychopharmacology (Berl)*.
74. Lord LD, Expert P, Atasoy S, Roseman L, Rapuano K, Lambiotte R, Nutt DJ, Deco G, **Carhart-Harris RL**, Kringelbach ML, Cabral J (2019) Dynamical exploration of the repertoire of brain networks at rest is modulated by psilocybin. *Neuroimage* 199:127-142.

73. **Carhart-Harris RL** & Friston KJ (2019) *REBUS and the anarchic brain: towards a unified model on the brain action of psychedelics. Pharmacological Reviews.*
72. Scott G & **Carhart-Harris R** (2019) *Psychedelics for disorders of consciousness. Journal of Consciousness Research.*
71. Atasoy S, Vohryzek J, Deco G, **Carhart-Harris RL**, Kringelbach ML (2018) *Common neural signatures of psychedelics: Frequency-specific energy changes and repertoire expansion revealed using connectome-harmonic decomposition. Prog Brain Res 242:97-120.*
70. **Carhart-Harris RL** (2018) *How do psychedelics work? Current Opinion in Psychiatry.*
69. Haijen EC, Kaelen M, Roseman L, Timmermann C, Russ C, Nutt D, Daws RE, Hampshire AD, Lorenz R, **Carhart-Harris RL** (2018) *Predicting responses to psychedelics: a prospective study. Front Psychol.*
68. Lyons T & **Carhart-Harris RL** (2018) *More Realistic Forecasting of Future Life Events After Psilocybin For Treatment-Resistant Depression. Front Psychol.*
67. Deco G, Cruzat J, Cabral J, Knudsen GM, **Carhart-Harris RL**, Whybrow PC, Logothetis NK, Kringelbach ML (2018) *Whole-Brain Multimodal Neuroimaging Model Using Serotonin Receptor Maps Explains Non-linear Functional Effects of LSD. Curr Biol. 28(19):3065-3074.e6.*
66. Millière R, **Carhart-Harris RL**, Roseman L, Trautwein FM, Berkovich-Ohana A (2018) *Psychedelics, Meditation, and Self-Consciousness. Front Psychol.*
- 65. Carhart-Harris RL (2018) Serotonin, psychedelics and psychiatry. World Psychiatry. 17(3):358-359.**
64. Timmermann C, Roseman L, Williams L, Erritzoe D, Martial C, Cassol H, Laureys S, Nutt D, **Carhart-Harris R** (2018) *DMT Models the Near-Death Experience. Front Psychol. 9:1424.*
63. Erritzoe D, Roseman L, Nour MM, MacLean K, Kaelen M, Nutt DJ, **Carhart-Harris RL** (2018) *Effects of psilocybin therapy on personality structure. Acta Psychiatr Scand.*

62. Gabay AS, **Carhart-Harris RL**, Mazibuko N, Kempton MJ, Morrison PD, Nutt DJ, Mehta MA (2018) Psilocybin and MDMA reduce costly punishment in the Ultimatum Game. *Sci Rep* 8(1):8236

61. **Carhart-Harris RL** (2018) The entropic brain - revisited. *Neuropharmacology*. pii: S0028-3908(18)30117-5.

60. **Carhart-Harris RL**, Roseman L, Haijen E, Erritzoe D, Watts R, Branchi I, Kaelen M (2018) Psychedelics and the essential importance of context. *J Psychopharmacol*. 2018 Feb 1;269881118754710. doi: 10.1177/0269881118754710.

59. Carrillo F, Sigman M, Fernández Slezak D, Ashton P, Fitzgerald L, Stroud J, Nutt DJ, **Carhart-Harris RL** (2018) Natural speech algorithm applied to baseline interview data can predict which patients will respond to psilocybin for treatment-resistant depression. *J Affect Disord*. 2018 Apr 1;230:84-86. doi: 10.1016/j.jad.2018.01.006.

58. Kaelen M, Giribaldi B, Raine J, Evans L, Timmerman C, Rodriguez N, Roseman L, Feilding A, Nutt D, **Carhart-Harris R** (2018) The hidden therapist: evidence for a central role of music in psychedelic therapy. *Psychopharmacology (Berl)*. 235(2):505-519. doi: 10.1007/s00213-017-4820-5.

57. Roseman L, Nutt DJ, **Carhart-Harris RL** (2018) Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression. *Front Pharmacol*.8:974. doi: 10.3389/fphar.2017.00974. eCollection 2017.

56. Roseman L, Demetriou L, Wall MB, Nutt DJ, **Carhart-Harris RL** (2017) Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression. *Neuropharmacology*. pii: S0028-3908(17)30639-1. doi: 10.1016/j.neuropharm.

55. Atasoy S, Roseman L, Kaelen M, Kringelbach M, Deco G, **Carhart-Harris RL** (2017) Connectome-harmonic decomposition of human brain activity reveals dynamical repertoire re-organization under LSD. *Sci Rep*.

54: Lyons T & **Carhart-Harris RL** (2017) Increased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression. *J Psychopharmacol*.

53: **Carhart-Harris RL**, Bolstridge M, Day CMJ, Rucker J, Watts R, Erritzoe DE, Kaelen M, Giribaldi B, Bloomfield M, Pilling S, Rickard JA, Forbes B, Feilding A, Taylor D, Curran HV, Nutt DJ (2017) Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. *Psychopharmacology (Berl)*.

- 52: Timmermann C, Spriggs MJ, Kaelen M, Leech R, Nutt DJ, Moran RJ, **Carhart-Harris RL**, Muthukumaraswamy SD (2017) LSD modulates effective connectivity and neural adaptation mechanisms in an auditory oddball paradigm. *Neuropharmacology*. pii: S0028-3908(17)30506-3.
- 51: Stroud JB, Freeman TP, Leech R, Hindocha C, Lawn W, Nutt DJ, Curran HV, **Carhart-Harris RL** (2017) Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression. *Psychopharmacology (Berl)*. [Epub ahead of print]
- 50: **Carhart-Harris RL**, Roseman L, Bolstridge M, Demetriou L, Pannekoek JN, Wall MB, Tanner M, Kaelen M, McGonigle J, Murphy K, Leech R, Curran HV, Nutt DJ (2017) Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. *Sci Rep*. 13;7(1):13187.
- 49: **Carhart-Harris RL**, Nutt DJ (2017) Serotonin and brain function: a tale of two receptors. *J Psychopharmacol*. 31(9):1091-1120.
- 48: **Carhart-Harris RL**, Erritzoe D, Haijen E, Kaelen M, Watts R (2017) Psychedelics and connectedness. *Psychopharmacology (Berl)*
47. Watts R, Day C, Krzanowski J, Nutt, DJ, **Carhart-Harris RL** (2017) Patients' accounts of increased 'connection' and 'acceptance' after psilocybin for treatment-resistant depression. *Journal of Humanistic Psychology*.
46. Nour MM, Evans L, **Carhart-Harris RL** (2017) Psychedelics, Personality and Political Perspectives. *J Psychoactive Drugs*. 2017 Apr 26:1-10. doi: 10.1080/02791072.2017.1312643. [Epub ahead of print]
45. **Carhart-Harris RL** & Goodwin GM (2017) The Therapeutic Potential of Psychedelic Drugs: Past, Present and Future. *Neuropsychopharmacology*. doi: 10.1038/npp.2017.84. [Epub ahead of print]
44. Schartner MM, **Carhart-Harris RL**, Barrett AB, Seth AK, Muthukumaraswamy SD (2017) Increased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin. *Nature Sci Rep*. 7:46421. doi: 10.1038/srep46421.
43. Walpola IC, Nest T, Roseman L, Erritzoe D, Feilding A, Nutt DJ, **Carhart-Harris RL** (2017) Altered Insula Connectivity under MDMA. *Neuropsychopharmacology*. doi: 10.1038/npp.2017.35.

42. **Carhart-Harris RL** & Nutt DJ (2016) Response to Letter 'Question based drug development for psilocybin'. *Lancet Psychiatry*. 3(9):807. doi: 10.1016/S2215-0366(16)30217-6.
- *41. **Carhart-Harris RL**, Bolstridge M, Rucker J, Day CM, Erritzoe D, Kaelen M, Bloomfield M, Rickard JA, Forbes B, Feilding A, Taylor D, Pilling S, Curran VH, Nutt DJ. (2016) Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. *Lancet Psychiatry* 3(7):619-27. doi: 10.1016/S2215-0366(16)30065-7.
40. Nour MM & **Carhart-Harris RL** (2016) Psychedelics and the science of self-experience. *British Journal of Psychiatry*. 210(3):177-179. doi: 10.1192/bjp.bp.116.194738.
39. Nour MM, Evans L, Nutt D and **Carhart-Harris RL** (2016) Ego-Dissolution and Psychedelics: Validation of the Ego-Dissolution Inventory (EDI). *Front. Hum. Neurosci.* 10:269. doi:10.3389/fnhum.2016.0026938.
38. Family N, Vinson D, Vigliocco G, Kaelen M, Bolstridge M, Nutt DJ, **Carhart-Harris RL** (2016). Semantic activation in LSD: evidence from picture naming. *Language, Cognition and Neuroscience*.
- 37: Lebedev AV, Kaelen M, Lövdén M, Nilsson J, Feilding A, Nutt DJ, **Carhart-Harris RL** (2016) LSD-induced entropic brain activity predicts subsequent personality change. *Hum Brain Mapp*. doi: 10.1002/hbm.23234.
- 36: Roseman L, Sereno MI, Leech R, Kaelen M, Orban C, McGonigle J, Feilding A, Nutt DJ, **Carhart-Harris RL** (2016) LSD alters eyes-closed functional connectivity within the early visual cortex in a retinotopic fashion. *Hum Brain Mapp*. doi: 10.1002/hbm.23224.
- 35: Tagliazucchi E, Roseman L, Kaelen M, Orban C, Muthukumaraswamy SD, Murphy K, Laufs H, Leech R, McGonigle J, Crossley N, Bullmore E, Williams T, Bolstridge M, Feilding A, Nutt DJ, **Carhart-Harris RL** (2016) Increased Global Functional Connectivity Correlates with LSD-Induced Ego Dissolution. *Curr Biol*. 25;26(8):1043-50. doi: 10.1016/j.cub.2016.02.010.
- 34: Kaelen M, Roseman L, Kahan J, Santos-Ribeiro A, Orban C, Lorenz R, Barrett FS, Bolstridge M, Williams T, Williams L, Wall MB, Feilding A, Muthukumaraswamy S, Nutt DJ, **Carhart-Harris RL** (2016) LSD modulates music-induced imagery via changes in parahippocampal connectivity. *Eur Neuropsychopharmacol*. pii: S0924-977X(16)30016-5. doi: 10.1016/j.euroneuro.2016.03.018.
- *33: **Carhart-Harris RL**, Muthukumaraswamy S, Roseman L, Kaelen M, Droog W, Murphy K, Tagliazucchi E, Schenberg EE, Nest T, Orban C, Leech R, Williams LT, Williams TM, Bolstridge M, Sessa B, McGonigle J, Sereno MI, Nichols D, Hellyer

- PJ, Hobden P, Evans J, Singh KD, Wise RG, Curran HV, Feilding A, Nutt DJ (2016) Neural correlates of the LSD experience revealed by multimodal neuroimaging. *Proc Natl Acad Sci U S A*. 113(17):4853-8. doi: 10.1073/pnas.1518377113.
- 32: Terhune DB, Luke DP, Kaelen M, Bolstridge M, Feilding A, Nutt D, **Carhart-Harris RL**, Ward J (2016) A placebo-controlled investigation of synaesthesia-like experiences under LSD. *Neuropsychologia*. pii: S0028-3932(16)30113-0. doi: 10.1016/j.neuropsychologia.2016.04.005.
- 31: Speth J, Speth C, Kaelen M, Schloerscheidt AM, Feilding A, Nutt DJ, **Carhart-Harris RL** (2016) Decreased mental time travel to the past correlates with default-mode network disintegration under lysergic acid diethylamide. *J Psychopharmacol* 30(4):344-53. doi: 10.1177/0269881116628430.
30. **Carhart-Harris RL**, Kaelen M, Bolstridge M, Williams TM, Williams LT, Underwood R, Feilding A, Nutt DJ (2016) The paradoxical psychological effects of lysergic acid diethylamide (LSD). *Psychol Med* 5:1-12.
29. Kaelen M, Barrett F, Roseman L, Lorenz R, Family N, Bolstridge M, Curran V, Feilding A, Nutt DJ, **Carhart-Harris RL** (2015) LSD enhances the emotional response to music. *Psychopharmacology* 232(19):3607-14.
28. Lebedev AV, Lövdén M, Rosenthal G, Feilding A, Nutt DJ, **Carhart-Harris RL** (2015) Finding the self by losing the self: Neural correlates of ego-dissolution under psilocybin. *Hum Brain Mapp*. doi: 10.1002/hbm.22833
27. Steeds H, **Carhart-Harris RL**, Stone JM (2015) Drug models of schizophrenia. *Ther Adv Psychopharmacol*. 2015 Feb;5(1):43-58. doi: 10.1177/2045125314557797
26. Turton S, Nutt DJ, **Carhart-Harris RL** (2015) A Qualitative Report on the Subjective Experience of Intravenous Psilocybin Administered in an fMRI Environment. *Curr Drug Abuse Rev*.
25. **Carhart-Harris RL**, Kaelen M, Whalley M, Bolstridge M, Feilding A, Nutt DJ (2014) LSD enhances suggestibility in healthy volunteers. *Psychopharmacology*. doi: 10.1007/s00213-014-3714-z.
24. **Carhart-Harris RL**, Kaelen M, Nutt DJ (2014) How do hallucinogens work on the brain? *The Psychologist*. 27 (9).
23. **Carhart-Harris RL** & Nutt (2014) Was it a vision or a waking dream? *Frontiers in Psychology*. doi: 10.3389/fpsyg.2014.00255.

22. Roseman L, Leech R, Feilding A, Nutt DJ, **Carhart-Harris RL** (2014) The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers. *Frontiers in Human Neuroscience*. doi: 10.3389/fnhum.2014.00204.
21. Muthukumuraswamy S, **Carhart-Harris RL***, Moran RJ, Brookes MJ, Williams TM, Erritzoe D, Sessa B, Papadopoulos A, Bolstridge M, Singh KD, Feilding A, Friston KJ, Nutt DJ et al. (2013) Broadband cortical desynchronization underlies the human psychedelic state. *J Neuroscience* 33(38):15171-83. doi: 10.1523/JNEUROSCI.2063-13.2013. * **Shared first authors**.
20. **Carhart-Harris RL**, Murphy K, Leech R, Erritzoe D, Wall MB, Ferguson B, Williams LT, Roseman L, Brugger S, De Meer I, Tanner M, Tyacke R, Wolff K, Sethi A, Bloomfield MA, Williams TM, Bolstridge M, Stewart L, Morgan C, Newbould RD, Feilding A, Curran HV, Nutt DJ (2014) The effects of acutely administered MDMA on spontaneous brain function measured with arterial spin labelling and BOLD resting-state functional connectivity. *Biol Psych*. doi: 10.1016/j.biopsych.2013.12.015.
19. **Carhart-Harris RL**, Wall MB, Erritzoe D, Kaelen M, Ferguson B, De Meer I, Tanner M, Bloomfield M, Williams TM, Bolstridge M, Stewart L, Morgan CJ, Newbould RD, Feilding A, Curran HV, Nutt DJ (2013) The effect of MDMA on recollecting autobiographical memories: an fMRI study with implications for MDMA-assisted psychotherapy. *Int J Neuropsychopharmacology* 17:1-14. doi: 10.1017/S1461145713001405.
- *18. **Carhart-Harris RL**, Leech R, Hellyer PJ, Shanahan M, Feilding A, Tagliazucchi E, Chialvo DR, Nutt DJ. (2014) The entropic brain: A theory of conscious states informed by neuroimaging research with psychedelic drugs. *Frontiers in Human Neuroscience*. doi: 10.3389/fnhum.2014.00020.
17. Tagliazucchi E, **Carhart-Harris RL**, Nutt DJ, Chialvo D (2014) Enhanced repertoire of brain dynamical states during the psychedelic experience. *Human Brain Mapping*. doi: 10.1002/hbm.22562
16. Leech R, Scott G, **Carhart-Harris RL**, Turkheimer F, Taylor-Robinson S, Sharp D (2013) A spatial relationship between task positive and task negative networks. *PloS One*.
15. Petri G, Expert P, Turkheimer F, Hellyer P, **Carhart-Harris RL** et al. (2014) Homological backbone of brain functional networks. *J R Soc Interface*. 11(101).
14. **Carhart-Harris RL**, Nutt DJ, Stone JM (2013) Psychiatry's next top-model: Cause for a re-think on drug models of psychosis and other psychiatric disorders. *Journal of Psychopharmacology* 27(9):771-8.

13. **Carhart-Harris RL & Nutt DJ (2013)** Experienced drug users assess the relative harms and benefits of drugs: a web-based survey. *Journal of Psychoactive drugs* 45(4):322-8.
- *12. **Carhart-Harris RL, Erritzoe D, Williams T, Stone JM, Reed LJ, Colasanti A, Tyacke RJ, Leech R, Malizia AL, Murphy K, Hobden P, Evans J, Feilding A, Wise RG, Nutt DJ (2012)** Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. *Proc Natl Acad Sci U S A* 109:2138-43.
11. **Carhart-Harris RL, R. Leech, D. Erritzoe, T. M. Williams, J. M. Stone, J. Evans, D. J. Sharp, A. Feilding, R. G. Wise, and D. J. Nutt (2012)** Functional Connectivity Measures after Psilocybin Inform a Novel Hypothesis of Early Psychosis. *Schizophr Bull* 39(6):1343-51.
10. **Carhart-Harris RL, Leech R, Williams TM, Erritzoe D, Abbasi N, Bargiotas T, Hobden P, Sharp DJ, Evans J, Feilding A, Wise RG, Nutt DJ (2012)** Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin. *Br J Psychiatry*. 200(3):238-44.
9. **Carhart-Harris RL & Friston KJ (2012)** Free-energy and Freud: an update. Ch 13. *From the couch to the lab: Trends in psychodynamic neuroscience*. Ed. Fotopoulou A et al. Oxford Books.
8. **Carhart-Harris RL, King LA, Nutt DJ (2011)** A web-based survey on mephedrone. *Drug Alcohol Depend* 118(1):19-22.
- *7. **Carhart-Harris RL, Friston KJ (2010)** The default-mode, ego-functions and free energy: a neurobiological account of Freudian ideas. *Brain* 133(4):1265-83.
6. **Carhart-Harris RL, Williams TM, Sessa B, Tyacke R, Feilding A, Nutt DJ (2010)** The administration of psilocybin to healthy hallucinogen-experienced volunteers in a mock-fMRI environment: a preliminary investigation of tolerability. *Journal of Psychopharmacology*. 25(11):1562-7.
5. **Carhart-Harris RL & Nutt DJ (2010)** User perceptions of the benefits and harms of hallucinogenic drug use: a web-based questionnaire study. *Journal of Substance Use* 15(4) 283-300.
4. **Carhart-Harris RL, Nutt DJ, Munafo MR, Christmas DM, Wilson SJ (2009)** Equivalent effects of acute tryptophan depletion on REM sleep in ecstasy users and controls. *Psychopharmacology (Berl)* 206(2):187-96
3. **Carhart-Harris RL, Nutt DJ, Munafo M, Wilson SJ (2009)** Current and former ecstasy users report different sleep to matched controls: a web-based questionnaire study. *J Psychopharmacol* 23(3):249-57

2. **Carhart-Harris RL**, Mayberg HS, Malizia ML, Nutt DJ (2008) Mourning & Melancholia revisited: Correspondences between principles of Freudian metapsychology and empirical findings in neuropsychiatry. *Annals of General Psychiatry* 7 (1): 9.

1. **Carhart-Harris RL** (2007) Waves of the unconscious. The neurophysiology of dreamlike phenomena and its implications for the psychodynamic model of the mind. *Neuropsychoanalysis* 9 (2):183-211.

A handwritten signature in black ink, appearing to read 'Robin Carhart-Harris', written in a cursive style.

Robin Carhart-Harris, PhD